Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

This study has been completed.
Information provided by (Responsible Party):
Nina Singh, University of Pittsburgh Identifier:
First received: February 11, 2009
Last updated: December 15, 2014
Last verified: December 2014
The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for the prevention of fungal diseases in liver transplant recipients

Condition Intervention Phase
Central Nervous System Fungal Infections
Lung Diseases, Fungal
Drug: Anidulafungin
Drug: Fluconazole
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Frequency of Fungal Infection [ Time Frame: 90 days post enrollment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Need for Additional Antifungal Therapy [ Time Frame: 90 days post enrollment ] [ Designated as safety issue: No ]

Enrollment: 200
Study Start Date: February 2010
Study Completion Date: May 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: anidulafungin
anti-fungal agent
Drug: Anidulafungin
200 mg IV loading dose followed by 100 mg qd for 21 days
Other Name: Eraxis
Active Comparator: Fluconazole
anti-fungal agent
Drug: Fluconazole
400 mg IV for 21 days
Other Name: DIFLUCAN

Detailed Description:

A number of well characterized risk factors have been shown to portend a high risk of opportunistic mycoses after liver transplantation.

Retransplantation and renal failure are amongst the most significant risk factors for invasive fungal infections in these patients.

Most Invasive fungal infections in these high-risk patients occur within the first month posttransplant.

Studies utilizing universal prophylaxis have primarily employed fluconazole. A recent meta-analysis of prophylactic trials documented a beneficial effect on morbidity and attributable mortality, but an emergence of infections due to non-albicans Candida spp. in patients receiving prophylaxis.

The availability of echinocandins has led to an expanded armamentarium of antifungal drugs with a potentially promising role as agents for targeted prophylaxis for invasive fungal infections in high-risk liver transplant recipients. Anidulafungin is unique amongst echinocandins in that it is eliminated from the body almost exclusively through biotransformation by slow non-enzymatic degradation in the blood, without hepatic metabolism or renal elimination. Anidulafungin has demonstrated good safety profile. We hypothesize that anidulafungin will be more effective and a better tolerated antifungal prophylactic agent in this setting.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Liver transplant recipient at increased risk for infection increased risk include any of the following:
  • retransplantation
  • renal replacement therapy (dialysis),
  • post transplant abdominal surgery (within 21days)
  • receipt of corticosteroids for greater than 14 days within the 4 weeks -preceding transplant
  • ICU care for greater than 48 hours at the time of transplantation
  • colonization with Candida sps within 4 weeks of transplantation
  • requirement of 15 units or greater of packed red cell transfusions
  • Intraoperative time exceeding 6 hours

Exclusion Criteria:

  • Hypersensitivity to azole or echinocandin antifungal agents
  • receipt of systemic antifungal therapy within 4 weeks prior to transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00841971

United States, California
UCLA Medical Cente
Los Angeles, California, United States, 90095
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
United States, Wisconsin
University of Wisconsin - Madison
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Nina Singh, MD University of Pittaburgh, VA Pittsburgh Health Systems
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nina Singh, MD, University of Pittsburgh Identifier: NCT00841971     History of Changes
Other Study ID Numbers: PRO08110001 
Study First Received: February 11, 2009
Results First Received: December 8, 2014
Last Updated: December 15, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Central Nervous System Fungal Infections
Lung Diseases
Lung Diseases, Fungal
Central Nervous System Diseases
Central Nervous System Infections
Nervous System Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
14-alpha Demethylase Inhibitors
Anti-Infective Agents
Antifungal Agents
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Steroid Synthesis Inhibitors processed this record on May 22, 2016